secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001326190-24-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025
---------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.
- Net loss for Q2 2024 was $24.6M ($0.35 per share) vs. $16.1M ($0.32 per share) in Q2 2023.
- Phase 2b IMPACT trial of pemvidutide in MASH enrollment progressing; topline data expected Q1 2025.
- End-of-Phase 2 FDA meeting for obesity program expected late Q3 2024 to discuss Phase 3 design.
- Phase 2 MOMENTUM obesity trial showed up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/0001326190-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000027/alt-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer